Pnm10 Cost Effectiveness of Memantine in the Treatment of Moderately Severe and Severe Alzheimer's Disease in Spain

Antoñanzas, Fernando; Badenas, Josep M.; François, Cindy; Guilhaume, C

doi:10.1016/s1098-3015(10)61949-3

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[100][101][102] Two further unpublished papers reporting on the costeffectiveness of memantine were provided by the manufacturer. 103,104 Also identified were three product-specific systematic reviews [105][106][107] and three broader systematic reviews 1,78,108 covering the costeffectiveness of included pharmaceuticals for AD.…”

Section: Results Of Literature Searchmentioning

confidence: 99%

“…Table 53 provides a summary of the study characteristics for the five economic evaluations reporting on the cost-effectiveness of memantine. [100][101][102][103][104] The studies represent countryspecific analyses for Finland, Norway, Spain and the UK, with a broadly similar methodology applied across all studies. Table 53 reports the 'headline' finding across studies of an improvement in time in autonomy (time spent in state defined as independent) together with cost savings over time (2 years 104 to 5 years) [100][101][102][103] (four of these studies reflect a societal perspective).…”

Section: Comments On Industry Submission For Galantaminementioning

confidence: 99%

“…[100][101][102][103][104] The studies represent countryspecific analyses for Finland, Norway, Spain and the UK, with a broadly similar methodology applied across all studies. Table 53 reports the 'headline' finding across studies of an improvement in time in autonomy (time spent in state defined as independent) together with cost savings over time (2 years 104 to 5 years) [100][101][102][103] (four of these studies reflect a societal perspective). Further detail on study findings from François and colleagues 103 and Jones and colleagues 104 is provided in Appendix 14, with detail on study characteristics and methods presented in Appendix 13.…”

Section: Comments On Industry Submission For Galantaminementioning

confidence: 99%

“…[100][101][102][103][104] Cost-effectiveness studies report cost reductions and improved outcomes; however, these are based on a number of assumptions. Those studies reporting non-UK cost-effectiveness estimates are based on a societal perspective and are not helpful in the UK context.…”

Section: Cost-effectiveness Of Memantinementioning

confidence: 99%

See 3 more Smart Citations

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

Loveman

Green²,

Kirby³

et al. 2006

Health Technol Assess

165

114

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAThe clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key ...

show abstract

Section: Results Of Literature Searchmentioning

confidence: 99%

Section: Comments On Industry Submission For Galantaminementioning

confidence: 99%

Section: Comments On Industry Submission For Galantaminementioning

confidence: 99%

Section: Cost-effectiveness Of Memantinementioning

confidence: 99%

See 2 more Smart Citations

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

Loveman

Green²,

Kirby³

et al. 2006

Health Technol Assess

165

114

View full text Add to dashboard Cite

show abstract

A Systematic Review of the Clinical and Cost-Effectiveness of Memantine in Patients with Moderately Severe to Severe Alzheimer???s Disease

et al. 2006

View full text Add to dashboard Cite

Alzheimer's disease (AD) is the most common form of dementia and is characterised by a worsening of cognition, functional ability, and behaviour and mood. The objective of this study was to review the clinical and cost-effectiveness of memantine for the treatment of patients with moderately severe to severe AD. To achieve this, a systematic search and review of the clinical and cost effectiveness literature for memantine was undertaken. The literature search covered the period from the inception of MEDLINE, Cochrane Library, EMBASE and other electronic databases until July 2004. The search included randomised controlled trials (RCTs) and full economic evaluations that assessed the use of memantine in patients with moderately severe to severe AD. Two published RCTs were included in this review; in one of these trials the participants were already being treated with donepezil. The two RCTs showed benefit for patients receiving memantine compared with placebo on the outcome measures of the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory modified for severe dementia, the Clinician's Interview-Based Impression of Change Plus Caregiver Input, and the Severe Impairment Battery, and that memantine appeared to be slightly more effective in patients already receiving a stable dose of donepezil. Five cost-effectiveness studies were included in the review. Although these studies reported cost reductions and improved outcomes with memantine, the evaluations were based on a number of assumptions. In conclusion, memantine appears to be beneficial when assessed using functional and global measurements. However, the effect of memantine on cognitive scores and behaviour and mood outcomes is less clear. Cost-effectiveness is dependent upon assumptions surrounding clinical effect and context-specific cost data.

show abstract

Modelling Disease Progression in??Alzheimer???s Disease

Green

2007

PharmacoEconomics

View full text Add to dashboard Cite

The literature reporting economic evaluations related to the treatment of Alzheimer's disease (AD) has developed over the last decade. Most analyses have used economic models to estimate the cost effectiveness of drugs for the treatment of AD. This review considers the range of methods used in the published cost-effectiveness literature to model AD progression and the effect of interventions on the progression of AD. The review builds on and updates an earlier systematic review of cost-effectiveness studies on drugs for AD. Systematic and rigorous methods were used to search the literature for economic evaluations estimating the cost effectiveness of donepezil, rivastigmine, galantamine or memantine in AD. The literature search covered a wide range of electronic databases (e.g. MEDLINE, EMBASE), and included literature from the inception of databases up to the end of 2005. The search identified 22 published economic evaluations. An outline and brief critical review of the identified studies is provided, and thereafter the methods used to model disease progression were considered in more detail. The review employs recent guidance on good practice in decision-analytic modelling in HTA to critically review the modelling methods used. Using this guidance, the models are assessed against the broad criteria of model structure, data inputs and assessment of uncertainty and inconsistency. Concerns were noted over the model structure employed in all models. The reliance on cognitive scores to model AD, the progression of the disease, and the effect of treatment on costs and consequences is regarded as a serious limitation in almost all of the studies identified. There are also limitations over the data used to populate published models, especially around the failure of studies to document and establish the basis for the modelling of treatment effects. It is also clear that studies modelling AD progression, and subsequently the cost effectiveness of treatment, have not addressed uncertainty or consistency (internal and/or external) in sufficient detail. Further research is required on more appropriate methods for the modelling of AD progression. In the meantime, future economic evaluations of treatment need to be more explicit on the methods used to model AD, and the data used to populate models.

show abstract

Pnm10 Cost Effectiveness of Memantine in the Treatment of Moderately Severe and Severe Alzheimer's Disease in Spain

Cited by 4 publications

References 0 publications

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

A Systematic Review of the Clinical and Cost-Effectiveness of Memantine in Patients with Moderately Severe to Severe Alzheimer???s Disease

Modelling Disease Progression in??Alzheimer???s Disease

Contact Info

Product

Resources

About